Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Company Drug

Allist Pharmaceuticals’ Furmonertinib Wins NMPA Nod for EGFR-Mutated NSCLC Treatment

Fineline Cube Aug 23, 2023

Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) has announced that it has received clinical approval from...

Company Drug

Zai Lab’s Repotrectinib Targets Breakthrough Therapy Designation for TRK-Positive Tumors

Fineline Cube Aug 23, 2023

The Center for Drug Evaluation (CDE) website has indicated that repotrectinib, a next-generation ROS1/TRK/ALK tyrosine...

Company Deals

Hangzhou Minsheng Healthcare Aims to Raise RMB890 Million in Shenzhen GEM IPO

Fineline Cube Aug 23, 2023

Hangzhou Minsheng Healthcare Co., Ltd. (SHE: 301507) is poised to raise RMB890 million through an...

Company Drug

RemeGen’s Telitacicept Shows Positive Phase III Results in Rheumatoid Arthritis Study

Fineline Cube Aug 23, 2023

China-based RemeGen Co., Ltd (HKG: 9995, SHA: 688331) has announced positive results from the China...

Company Deals

Shanxi Jinbo Bio-pharmaceutical Plans Fundraise with Private Placement and IPO Proceeds

Fineline Cube Aug 23, 2023

China-based Shanxi Jinbo Bio-pharmaceutical Co., Ltd. (832982.BSE) is poised to raise RMB 36.75 million through...

Policy / Regulatory

CCDI Cartoon Exposes “Prescription Data Rebates” Corruption in China’s Healthcare System

Fineline Cube Aug 23, 2023

China’s Central Commission for Discipline Inspection (CCDI), the country’s anti-graft bureau, has released a cartoon...

Company Drug

Roche Subsidiary Genentech Addresses Accidental Disclosure of Tiragolumab Trial Data

Fineline Cube Aug 23, 2023

Swiss pharmaceutical major Roche (SWX: ROG), through its subsidiary Genentech, has released a statement addressing...

Policy / Regulatory

Shanghai Updates Biomedical R&D Import Pilot for Streamlined Customs Clearance

Fineline Cube Aug 23, 2023

The Shanghai Municipal Commission of Commerce, in collaboration with Shanghai Customs and the Shanghai Municipal...

Company Deals

Bayer Partners with Mahana Therapeutics to Market Digital Health Technologies

Fineline Cube Aug 23, 2023

Germany-headquartered Bayer (ETR: BAYN) has announced a strategic partnership with US digital developer Mahana Therapeutics....

Company Drug

European Commission Grants Conditional Approval for Janssen’s Talvey in Multiple Myeloma

Fineline Cube Aug 23, 2023

The European Commission (EC) has granted conditional approval to Johnson & Johnson’s (J&J; NYSE: JNJ)...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Fluzoparib Files for New Indication with China’s NMPA

Fineline Cube Aug 23, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that the National Medical Products...

Company Drug

Kintor Pharmaceutical Completes Enrollment in Phase II Study of GT20029 for Androgenetic Alopecia

Fineline Cube Aug 23, 2023

China-based Kintor Pharmaceutical Limited (HKG: 9939) has announced the completion of patient enrollment in a...

Company Drug

Novartis’s Leqvio (Inclisiran) Approved in China for Hypercholesterolemia Treatment

Fineline Cube Aug 23, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has received approval from the National Medical Products Administration...

Company Drug

Novatim’s KQ-2003 and KY-0118 Advance with Clinical Trial Approvals in China

Fineline Cube Aug 22, 2023

China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd has recently obtained clinical trial...

Company Drug

Sichuan Huiyu Pharmaceutical’s Plerixafor Gains Marketing Approval from Italian Medicines Agency

Fineline Cube Aug 22, 2023

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Medical Device

Lifetech Scientific Corporation Receives NMPA Approval for Epione Navigation System

Fineline Cube Aug 22, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced that it has received market approval from...

Company Deals

Jiahui Health and Gleneagles Hong Kong Hospital Partner for Integrated Healthcare Services

Fineline Cube Aug 22, 2023

China-based Jiahui Health has entered into a strategic partnership with Gleneagles Hong Kong Hospital to...

Company Deals

Saints Sages Surgical Secures Series B Funding to Advance Energy-Based Devices

Fineline Cube Aug 22, 2023

Shanghai-based Saints Sages Surgical Co., Ltd, a leading developer of high-value minimally invasive surgical products,...

Company Drug

Hainan Huluwa Pharmaceutical Gets NMPA Approval for Generic Briviact Clinical Study

Fineline Cube Aug 22, 2023

China-based Hainan Huluwa Pharmaceutical Group Co., Ltd (SHA: 605199) has announced that it has received...

Company Deals

CSPC Pharmaceutical Group Partners with Insilico and XtalPi for AI-Driven Drug R&D

Fineline Cube Aug 22, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced strategic partnership agreements with Insilico Medicine...

Posts pagination

1 … 421 422 423 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.